Coronis Neurosciences
Neurocognitive and Neurodegenerative Therapies
Company Name | Updating Date | Neurotech Category | Market Category | Target Market | Technologies | Company Founded Year | Company Number of Employees |
|---|---|---|---|---|---|---|---|
Coronis Neurosciences | 02/07/2022 | NeuroPharmacology | NeuroBioTechnology | Biotechnology & Biopharmaceutical | Clinical use (of cognitive, psychological, psychiatric, inc. early diagnosis) | Biochemical: pharmacological drugs (Developing drugs) | 01/01/2014 | "1-10" |
Coronis Neurosciences is a specialty pharmaceutical company focused on the development of therapies for neurocognitive and neurodegenerative disorders. Coronis owns a pipeline of several clinical- and preclinical-stage molecules and strives to build value through the clinical development of proprietary formulated drugs.
The company's pipeline includes CP201, its leading drug, developed to treat ADNP syndrome. CP201 is a trans-nasally delivered peptide (NAP) developed for the treatment of ADNP syndrome in children. ADNP syndrome, an autism spectrum disorder, is a rare neurogenetic disease caused by de novo mutations in the ADNP gene.
Coronis also develops CP101, a drug to treat cognitive impairment associated with schizophrenia (CIAS) using a proprietary new small peptide.